<DOC>
	<DOCNO>NCT00003850</DOCNO>
	<brief_summary>Phase II trial study effectiveness thalidomide treat patient recurrent metastatic head neck cancer . Thalidomide may stop growth head neck cancer stop blood flow tumor .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect thalidomide survival patient recurrent metastatic squamous cell carcinoma head neck . II . Determine clinical response rate follow therapy patient . III . Determine toxic effect thalidomide patient . IV . Determine effect thalidomide tumor angiogenesis patient . OUTLINE : Patients receive 4-20 capsule oral thalidomide daily . Dose escalate individual patient weekly basis first 5 week . Treatment continue absence disease progression unacceptable toxicity , 12 month past complete response .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma head neck Recurrent disease OR metastatic disease initial diagnosis recurrence Initial therapy surgery and/or radiotherapy , induction chemotherapy , concurrent chemotherapy radiotherapy allow No one prior regimen chemotherapy biologic therapy metastatic disease Recurrence adjuvant induction chemotherapy may receive one additional course chemotherapy biologic therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 3 month WBC least 3000/mm3 Platelet count least 100,000/mm3 Hematocrit least 30 % Bilirubin great 1.5 time normal SGOT/SGPT great 1.5 time normal Creatinine great 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile woman must use 2 method effective contraception , 1 barrier 1 hormonal , begin least 4 week study continue 1 month study Men must use effective barrier contraception 1 month study No grade 2 great peripheral neuropathy No serious infection concurrent illness require immediate therapy Must able take oral medication No medical social factor would interfere compliance PRIOR CONCURRENT THERAPY : Any number course one regimen chemotherapy allow No concurrent cytotoxic chemotherapy No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>